However, NSCLC patients with either exclusively nuclear or combined nuclear/cytoplasmic expression of APE1 had almost the same median PFS (8.4 vs. 7.7 months) and OS (10.7 vs. 11.1 months). Here, APEX1 is linked to non-small cell lung carcinoma.